Zenith Capital Corp. (ZHCLF)

Market Cap	27.39M +85,863.1%
Revenue (ttm)	n/a
Net Income	-7.94M
EPS	-0.05
Shares Out	161.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,250
Open	0.1700
Previous Close	0.0020
Day's Range	0.1700 - 0.1700
52-Week Range	0.0003 - 0.1900
Beta	626.84
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 2, 2026

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZHCLF

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error